Seqirus, a global leader in influenza prevention, announced today it has begun shipping its portfolio of seasonal influenza vaccines to customers in the
Seqirus is one of the world's largest influenza vaccine companies and is well-positioned to supply up to 60 million doses for the U.S. market this year, depending on demand.
'We are collaborating with our partners across the industry to ensure a reliable supply of influenza vaccines throughout the season to help as many eligible people as possible get an influenza vaccination,' said
Seqirus has a broad portfolio of differentiated products for individuals six months of age to adults 65 years and older, presented in pre-filled syringes as well as multi-dose vials.[3],[4],[5],[6]
This year Seqirus will provide FLUAD (Influenza Vaccine, Adjuvanted), the first-and-only adjuvanted seasonal influenza vaccine approved for adults 65 and older, in addition to FLUAD Quadrivalent (Influenza Vaccine, Adjuvanted). FLUAD Quadrivalent contains an additional B strain to help prevent disease caused by all 4 influenza strains represented in the vaccine.3,4 The Seqirus 2020/21 influenza vaccine portfolio also includes FLUCELVAX QUADRIVALENT (Influenza Vaccine), a cell-based quadrivalent influenza vaccine approved for use in persons 4 years of age and older5 and AFLURIA QUADRIVALENT (Influenza Vaccine), an egg-based quadrivalent influenza vaccine approved for use in those six months of age and older.6
'Influenza vaccination is critical every year, and it is more important than ever this season as it can help reduce the risk of co-infection from seasonal influenza and COVID-19 and minimize the burden of flu on the healthcare system to preserve capacity for patients with COVID-19 and other serious disorders,' said
Seqirus produces influenza vaccines across its global manufacturing network, which includes facilities in the
'We are exploring all possibilities to optimize supply across our global network to help meet the additional demand for the 2020/21 influenza season,' said
About Seasonal Influenza
Influenza is a common, highly contagious infectious disease that may cause severe illness and life-threatening complications in some people.[7] To reduce the risk of more serious outcomes, such as hospitalization and death resulting from influenza, the
About Seqirus
Seqirus is part of
About CSL
CSL (ASX:CSL) is a leading global biotechnology company with a dynamic portfolio of life-saving medicines, including those that treat hemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL - including our two businesses, CSL Behring and Seqirus provides life-saving products to more than 70 countries and employs more than 27,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest.
Forward-Looking Statements
This press release may contain forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements.
Contact:
Tel: +1 (908) 608-7170
Email: Polina.Miklush@Seqirus.com
(C) 2020 Electronic News Publishing, source